CCL18/CCR6 may therefore be a candidate for intervention in atherosclerosis-related inflammation, albeit that our limited understanding of chemokine pathways relevant to human atherosclerosis, in mutual interaction, warrants further study. This evidence concerns the gene CCR6 and atherosclerosis.